News from Zentiva

May 20, 2021    /    Featured

Zentiva to further invest into their Prague manufacturing site

Prague – May 20, 2021 – Zentiva, the largest supplier of medicines to the Czech patients and the Czech market, will invest a further 27 million Euros into its Flagship Prague Manufacturing facility as part of a continuing capacity expansion programme. This investment follows on from the 35 million Euros invested at the Prague site over the last three years.

“The supply of medicines is more important than ever. At Zentiva we respond to the needs of the people in Europe and beyond who trust and depend on Zentiva medicines every day. We take the responsibility to make high quality medicines affordable and accessible. By investing in our manufacturing sites, into our business and into our team we will continue our growth story”, stated Safak Oner, Head of Industrial Operations.

High speed production lines have been commissioned and installed in the Prague site to respond to the accelerating demand for Zentiva medicines. 2020 saw the Prague site deliver a record 129 million packs of medicine which will be again surpassed in 2021.

Through the investments made so far Zentiva has been able to rapidly increase supply of vital medicines such as noradrenaline used in intensive care and dexamethasone used for treating Covid patients. The new investments will support the further production of cardiovascular medicines, medicines to support mental health and provide the technology base for the development new oncology value-added medicines.

Safak Oner: “ We are very proud that the heart of our business is in the Czech Republic. The strong investment programme will also help create new employment opportunities and further strengthen our contribution to the science and technology base here in Prague and across the Czech Republic.“

Zentiva is a leading supplier of high quality-affordable medicines across Europe with its headquarters in Prague.

About Zentiva

Zentiva is a producer of high-quality affordable medicines serving patients in Europe and beyond. With a dedicated team of more than 4,500 people and a network of production sites - including flagship sites in Prague, Bucharest, and Ankleshwar - Zentiva strives to be the champion of branded and generic medicines in Europe to better support people’s daily healthcare needs.
At Zentiva it is our aspiration that healthcare should be a right and not a privilege. More than ever, people need better access to high-quality affordable medicines and healthcare. We work in partnership with physicians, pharmacists, wholesalers, regulators, and governments to provide the everyday solutions that we all depend on. Learn more about Zentiva.com.

Media Contact

Mounira Lemoui
Head of Communications
ZENTIVA GROUP, a.s.
U kabelovny 529/16, Dolní Měcholupy, 102 00 Prague 10
Mobil: (+420) 727 873 159
E-mail:
mounira.lemoui@zentiva.com